Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : For source : Www.biospace.com save search
BioMarin Reports Record Financial Results for the First Quarter 2024
Published: 2024-04-24 (Crawled : 00:00) - biospace.com/
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
first for financial results
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Published: 2024-04-24 (Crawled : 22:00) - biospace.com/
PLSE | $6.86 0.0% 130K
|
Health Technology
|
| O: 0.87%
H: 0.14%
C: -0.87%
first conference for financial results
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
PGEN | $1.42 1.43% 1.41% 560K
|
Health Technology
|
| O: 0.0%
H: 2.14%
C: 1.43%
prgn-2012 respiratory asco treatment immunotherapy for meeting study
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
NVCR | $12.35 2.45% 2.39% 1.1M
|
Health Technology
|
| O: 0.33%
H: 2.48%
C: 2.07%
lung asco cancer cell for trial results
First Approval for Rare Pediatric Cancer; New OTC Opioid Overdose Option
Published: 2024-04-24 (Crawled : 16:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: -1.05%
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: -0.03%
H: 2.66%
C: 2.46%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.82%
H: 0.37%
C: 0.17%
XOMA | $25.11 -3.76% -3.9% 8.2K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: -1.91%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
rare first opioid approval for
BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior ExchangeStrategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
BSEM | $9.24 -38.71% 32K
|
n/a
|
| O: 0.0%
H: 1.73%
C: 1.3%
for set market
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
SNPX | $4.6 0.66% 0.65% 14K
|
Professional, Scientific, and T...
|
| O: 0.22%
H: 2.4%
C: -0.44%
nasdaq for
GoodRx Announces Date for 2024 Investor Day
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
GDRX 4 | $6.96 -0.14% -0.14% 610K
|
Technology Services
|
| O: 5.26%
H: 1.86%
C: -0.57%
day for
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
AMRX | $6.07 12.41% 11.04% 3.1M
|
Health Technology
|
| O: 6.67%
H: 6.08%
C: 5.03%
fda opioid approval treatment for spray
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
ARWR | $23.285 -2.08% -2.13% 810K
|
Health Technology
|
| O: -0.17%
H: 0.08%
C: -1.9%
disease kidney treatment pharmaceuticals for study
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
Published: 2024-04-24 (Crawled : 13:00) - biospace.com/
NTRB | $3.56 -8.76% 3.4K
|
Manufacturing
|
| O: 3.37%
H: 5.71%
C: 4.62%
fda transdermal for commercial development submission
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Published: 2024-04-24 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: -1.05%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
CVAC | $2.51 -3.46% -3.59% 1.1M
|
Health Technology
|
| O: -4.62%
H: 4.44%
C: 1.21%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 0.11%
H: 0.97%
C: -0.56%
business update for financial results
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
INVA | $15.15 -0.13% -0.13% 420K
|
Health Technology
|
| O: 1.03%
H: 0.72%
C: -0.13%
positive treatment global for
Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
XOMA | $25.11 -3.76% -3.9% 8.2K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: -1.91%
day fda approval tumor for
Boston Scientific Announces Results for First Quarter 2024
Published: 2024-04-24 (Crawled : 11:00) - biospace.com/
BSX | $72.91 5.68% -0.03% 15M
|
Health Technology
|
| O: 7.19%
H: 1.71%
C: -0.31%
AXNX | $66.67 0.3% 0.3% 400K
|
Health Technology
|
| O: -0.06%
H: 0.45%
C: 0.21%
first for results
Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development
Published: 2024-04-24 (Crawled : 08:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
drug for therapeutics development
Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)
Published: 2024-04-23 (Crawled : 00:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
first drug authorized food depression treatment clearance for therapeutics
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Published: 2024-04-23 (Crawled : 00:00) - biospace.com/
MCUJF | $0.6797 0% 130
|
Health Technology
|
| O: -5.56%
H: 0.0%
C: 0.0%
fda designation for
Electromed, Inc. Schedules its Third Quarter Fiscal 2024 Financial Results Conference Call for May 7, 2024 at 5:00 p.m. ET
Published: 2024-04-23 (Crawled : 14:30) - biospace.com/
ELMD | $16.73 2.07% 0.0% 21K
|
Health Technology
|
| O: 0.06%
H: 4.83%
C: 4.2%
conference for financial results
Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial
Published: 2024-04-23 (Crawled : 14:30) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
drug candidate treatment for trial response
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.